To advance the discovery of targetable factors for cancer therapy, we focused on CCT, which is a type II eukaryotic chaperonin that is composed of two stacked rings consisting of eight distinct subunits (CCT1-8) that form the protein folding chamber. Here, FLVCR2 is linked to cancer.